Claims

1. A method of producing a colloidal preparation comprising cationic colloidal nanoparticles and an active agent comprising the steps of
   a) providing an active agent,
   b) providing empty cationic nanoparticles comprising a cationic component and
   c) incubating said active agent of step a) with the empty cationic colloidal nanoparticles of step b) in an aqueous medium for a period of time sufficient to cause loading of said agent into said cationic nanoparticles,

   wherein step c) is performed without further steps as a self-assembly process.

2. The method of claim 1, wherein said active agent is water soluble and/or comprises an anionic moiety and a moiety which can interact by amphiphilic interactions and wherein said active agent has a high partition coefficient into said nanoparticles in an aqueous solution.

3. The method of claims 1 or 2, wherein said active agent is present in an amount of about 0.1 mol% to less than about 100 mol%, preferably from about 1 mol% to about 50 mol%, more preferably from about 3 mol% to about 30 mol% and most preferably from about 5 mol% to about 10 mol% with respect to the amount of said cationic component of said cationic nanoparticles of step b).

4. The method of any one of claims 1 to 3, wherein said active agent is selected from a camptothecin drug in the carboxylate form.

5. The method of claim 4, wherein said camptothecin drug is selected from camptothecin, 10-OH-CPT or SN38.

6. The method of claims 4 or 5, wherein the lactone form of a camptothecin drug is present in said preparation in an amount of below about 10%, preferably of below about 8%, more preferably of below about 6% and more preferably of below about 4% with respect to the total amount of the carboxylate drug.

7. The method of any one of the claims 4 to 6, wherein said camptothecin drug can be present as an aqueous solution or a solid product.

8. The method of any one of claims 1 to 7, wherein said cationic nanoparticles of step b) are selected from micelles, liposomes and nanocapsules.

9. The method of any one of the claims 1 to 8, wherein said empty cationic nanoparticles of step b) can be present as an aqueous dispersion or a solid product.

10. The method of any one of claims 1 to 9, wherein said cationic nanoparticles of step b) comprise as cationic component cationic amphiphiles or polymers, particularly cationic polyelectrolytes.

11. The method of any one of the claims 1 to 10, wherein said cationic nanoparticles of step b) comprise as cationic component cationic lipids, particularly cationic lipids selected from DOTAP or DMTAP.

12. The method of any one of the claims 1 to 11, wherein said incubation time of step c) is between about 10 min and about 6 hours, preferably between about 30 min and about 2 hours.

13. The method of any one of the claims 1 to 12, wherein said incubation temperature of step c) is between about 4°C and about 25°C, preferably about 25°C.

14. The method of any one of claims 1 to 13, wherein said preparation is obtained after c) and which is suitable for immediately, e. g. directly administering it to a subject in need thereof.

15. The method of any one of the claims 1 to 14, wherein said colloidal preparation has a pH in the range of about 6 to about 8.

16. Use of a colloidal preparation produced by a method of any one of claims 1 to 15 for the manufacture of a medicament for an angiogenesis-associated disease.

17. A pharmaceutical composition comprising a colloidal preparation produced by a method of any one of claims 1 to 15, optionally together with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

18. Kit comprising a) an active agent, b) empty cationic nanoparticles and optionally c) an aqueous medium, wherein said active agent is water soluble and/or comprises an anionic moiety and a moiety which can interact by amphiphilic interactions and wherein said active agent has a high partition coefficient into said nanoparticles in an aqueous solution, wherein the components a), b) and optionally c) are in separate containers.

19. The kit of claim 18, wherein said active agent is a camptothecin drug in the carboxylate form.

20. The kit of claims 18 or 19 for the manufacture of a pharmaceutical composition.

21. The kit of anyone of claims 18 to 20 for the manufacture of a medicament for an angiogenesis associated disease such as cancer.